Table 1 Patients’ characteristics and TP53 mutation in 132 patients with AML/ MDS
From: TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
Factors | Number of AML/ MDS patients N (%) | TP53 mutated patients N (%) | P |
|---|---|---|---|
Age, range 16–93 years (N = 132) | 0.575 | ||
< 60 years | 69 (52.3) | 6/69 (8.7) | |
> 60 years | 63 (47.7) | 8//63 (12.7) | |
Disease (N = 132) | 0.003 | ||
De novo AML | 87 (65.9) | 8/87 (9.2) | |
Secondary AML | 17 (12.9) | 3/17 (17.6) | |
MDS (excess blast) | 24 (18.2) | 1/24 (4.2) | |
T-AML/MDS | 4 (3.0) | 2/4 (50) | |
White blood cell count in AML patients (N = 107) | 0.563 | ||
< 100,000/μL | 88 (82.2) | 12/88 (13.6) | |
> 100,000/μL | 19 (17.8) | 0/19 (0) | |
Chromosome analysis (N = 132) | 0.016 | ||
Abnormal | 67 (50.8) | 12//67 (17.9) | |
Normal | 65 (49.2) | 2/65 (3.1) | |
Cytogenetic risk (N = 132) | 0.01 | ||
Favorable | 6 (4.5) | 0/6 (0) | |
Intermediate | 89 (67.4) | 5/89 (5.6) | |
Unfavorable | 37 (28) | 9/37 (24.3) | |
Complex chromosome (N = 132) | 0.004 | ||
Yes | 24 (18.2) | 7/24 (29.2) | |
No | 108 (81.8) | 7/108 (6.5) | |
Complex with monosomy karyotype (N = 132) | 0.008 | ||
Yes | 14 (10.6) | 5/14 (35.7) | |
No | 118 (89.4) | 9/118 (7.6) | |
Complex with del5/−5 or del7/−7 (N = 132) | 0.026 | ||
Yes | 12 (9.0) | 4/12 (33.3) | |
No | 120 (91.0) | 10/120 (8.3) | |
Monosomy (N = 132) | 0.002 | ||
Yes | 21 (15.9) | 7/21 (33.3) | |
No | 111 (84.1) | 7/111 (6.3) | |
Gene mutation (N = 107 AML patients) | 0.893 | ||
FLT3-ITD | 13 (12.1) | 3/13 (23) | |
NPM1 | 26 (24.3) | 3/26 (11.5) | |
CEBPA | 9 (8.4) | 0/9 (0) | |
No mutation | 80 (74.8) | 10/80 (12.5) |